PROGENICS PHARMACEUTICALS INC

Progenics Pharmaceuticals Inc. specializes in the manufacturing of radiopharmaceutical preparations, with a demonstrated focus on producing diagnostic agents for oncology applications, particularly fluorine-18 labeled compounds such as Pylarify (piflufolastat F-18). The company’s technical expertise lies in GMP-compliant radiopharmaceutical synthesis, radiochemistry process development, and the scalable production of targeted PET imaging agents under strict regulatory frameworks. Their specialization in short-half-life isotopes requires advanced logistics, precision dosing, and cold-chain distribution capabilities, positioning them as a critical supplier in nuclear medicine diagnostics. The contractor maintains a primary relationship with the Department of Veterans Affairs, supplying specialized radiopharmaceuticals for clinical use in veteran healthcare facilities. This sustained engagement suggests deep integration into VA’s nuclear medicine supply chain, likely supporting prostate cancer imaging and other oncologic diagnostics. Limited engagements with other federal contracting offices indicate targeted, mission-specific procurements, possibly for research or pilot programs involving novel radiotracers. The primary NAICS code 325412 reflects core activity in pharmaceutical preparation manufacturing, specifically the formulation and production of radiopharmaceuticals for diagnostic use. The company’s market positioning is narrow and highly specialized, serving the niche but critical segment of molecular imaging agents within the federal healthcare ecosystem. Their work supports precision diagnostics, enabling early detection and staging of disease through targeted PET imaging. Progenics Pharmaceuticals Inc. is a small business entity headquartered in North Billerica, Massachusetts, with no disclosed government certifications. Its geographic presence is centralized, suggesting a focused operational footprint optimized for controlled radiopharmaceutical production and distribution. The company’s government market positioning is that of a trusted, high-compliance supplier in a regulated therapeutic area requiring stringent quality controls and regulatory adherence.